Public Health Initiatives

To Meaningfully Address the Opioid Crisis, Purdue is Pursuing Three Public Health Initiatives

The Initiatives seek to help individuals suffering from opioid use disorder or overdose by developing and providing millions of doses of three medicines in two categories:

1. Opioid Use Disorder Treatment - one of three FDA approved treatments for opioid dependence, to be used as part of a complete treatment plan that includes counseling and psychosocial support. Purdue donates a portion of the product to qualified organizations to reach those with no insurance coverage who may not be able to afford treatment.

2. Opioid Overdose Treatments

a) An injectable medicine approved by FDA in February 2022 that has the potential to reverse overdoses of powerful synthetic opioids such as fentanyl. Purdue is offering this product at low cost and no profit to the Company. Click here to learn more.

Additional delivery systems are in development (prefilled syringe, autoinjector)* to provide options for a broad range of users.

b) Subject to FDA approval, an investigational drug* that will provide low‐cost, nonprescription intranasal naloxone similar to Narcan®.

Collectively, these Initiatives are intended to increase access to treatments for opioid use disorder and overdose reversal.

*These products are not approved by the U.S. Food and Drug Administration, and safety or effectiveness have not been established. There is no guarantee that these products will successfully complete development or gain FDA approval.